INVINCIBLE TRIAL: Intratumoural INT230-6 in Breast Cancer

Official Title

A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoural INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial


This is a phase II, randomized, multi-centre, parallel design, window of opportunity trial evaluating intratumoural INT230-6 in up to 90 patients with early stage breast cancer. In a 2:1 randomization, patients on the treatment arm will receive intratumoural INT230-6 injections prior to breast surgery.

Trial Description

Primary Outcome:

  • The proportion of patients achieving a CCCA defined as a reduction in the proportion of cells staining positive for Ki67 as assessed by immunohistochemistry to less than a natural logarithm, or ≤2.7%, at the post-treatment specimen.
Secondary Outcome:
  • The proportion of patients that achieved a complete pathologic response on surgical pathology as measured by the residual cancer burden index
  • Immunohistochemical and gene expression markers of necrosis, apoptosis and tumour proliferation pathways.
  • Markers of immunomodulation including macrophages, NK, DC, CD4 T-cells, CD8 T-cells, regulatory T-cells.
  • Adverse effects of INT230-6 injected to breast cancers in healthy patients prior to surgery.

The study comprises 2 consecutive parts. The first part will be to test safety and feasibility of the dosing procedures. Results from Part I of the study will standardize the optimal dose and frequency of INT230-6 for participants in Part II.

Part I: Open-label 2:1 randomized study of up to 30 patients. Treatment arm patients will be given up to 3 doses of INT230-6 injected weekly prior to breast surgery, at a dose based on longest diameter. The control arm patients receive no treatment.

Part II: Double-blind, 2:1 randomized study of up to an additional 60 patients. The placebo arm includes a saline injection of similar dose and frequency as the treatment arm (up to 2 doses of INT230-6/saline injected weekly prior to breast surgery).

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society